Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial.
about
Geriatric considerations in the treatment of advanced prostate cancerImpact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel.The importance of supportive care in optimizing treatment outcomes of patients with advanced prostate cancer.Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions.Management of advanced prostate cancer in senior adults: the new landscape.Drug design strategies for the treatment of prostate cancer.Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer.Treatment of Metastatic Prostate Cancer in Older Adults.Use of palliative chemotherapy in patients aged 80 years and over with incurable cancer: experience at three Sydney cancer centres.Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.Docetaxel in very elderly men with metastatic castration-resistant prostate cancer.Low-dose docetaxel, estramustine and prednisolone combination chemotherapy for castration-resistant prostate cancer.Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study.Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.Using Information Technology in the Assessment and Monitoring of Geriatric Oncology Patients.
P2860
Q33598327-39002843-03E6-4521-9AE2-66F9E498E97BQ36490409-3D49FB97-BFA9-4149-ABB9-AF26CCC886C6Q36672788-8E0C3BA6-4D2D-4144-A76F-398BF9429B05Q37538483-8820176E-0D63-4E3B-8DEF-105353A4380AQ38046826-8B906A81-1769-45AA-98B3-A6A1AF1E8DAAQ38264673-3F35F8B1-7B1E-4C53-9349-5D02646BED71Q38699712-79633932-73EC-4AFA-87B7-1430CD5A7E05Q38944255-C315873D-52F8-4423-BD12-9F4D9898CAEAQ39282806-BEE8A5A7-100D-4992-9D1A-34CA0245F87BQ39612278-7DAAE9C1-D58D-44D5-AD91-5B822D326C70Q41275386-AF28F21E-8725-44D7-9B85-9F239D9CB281Q42748400-740F3C63-5EBD-43D8-81DC-9B1F59AB97C1Q47127978-8F3924E8-1110-4FBF-AEA6-D639E1DE5A8AQ48272997-4B02C2B5-B014-4289-831D-B1185E4CE5A9Q52364992-297023DA-5338-45A9-A3FF-0CB5F6A15A44
P2860
Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Tolerability and efficacy of d ...... (mCRPC) in the TAX 327 trial.
@ast
Tolerability and efficacy of d ...... (mCRPC) in the TAX 327 trial.
@en
type
label
Tolerability and efficacy of d ...... (mCRPC) in the TAX 327 trial.
@ast
Tolerability and efficacy of d ...... (mCRPC) in the TAX 327 trial.
@en
prefLabel
Tolerability and efficacy of d ...... (mCRPC) in the TAX 327 trial.
@ast
Tolerability and efficacy of d ...... (mCRPC) in the TAX 327 trial.
@en
P2093
P2860
P1476
Tolerability and efficacy of d ...... r (mCRPC) in the TAX 327 trial
@en
P2093
Anne M Horgan
Bostjan Seruga
Greg R Pond
Ian F Tannock
Mario A Eisenberger
Ronald De Wit
Shabbir M Alibhai
P2860
P304
P356
10.1016/J.JGO.2013.12.001
P50
P577
2014-01-02T00:00:00Z